All shorts have been covered on this stock. Southridge has a credit line arrangement with a bottomless floor on conversions - death spiral financing. Southridge and Asher are out of the game right now. With the loss of their massive selling pressure the stock is rising. But they also know that this stock has been hugely diluted - I would bet that we are now closing in on 1B shares issued. Look for Southridge and Asher to begin selling short again, and soon.
Besides the timing doesn't jive on their 11/19/12 announcement of IND and Clinical trials; they said they had HIRED Cascade Life Sciences for research, not that CLS had already been conducting research and that they would begin process for IND in Q4 with clinical trials in 2013-14. It takes a MINIMUM 6 mo to gather sufficient data for IND application and 6-9 mo for application process. If they just hired CLS in November, how will they apply for IND by the end of December? Besides, where will the money come from? The answer is Asher and Southridge, with another round of short selling and the final death spiral. JMO, but the smart money is on this thing tanking before the end of Q2 2013. The only way to profit on this one is to short it.